Advertisement

Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules

Published:November 28, 2021DOI:https://doi.org/10.1016/j.jhep.2021.11.023

      Highlights

      • F4 patients without non-characterized liver nodules remained at risk of HCC after HCV cure.
      • All cases of HCC were observed in patients with a history of decompensation and/or clinically significant portal hypertension.
      • None of the 63 F3 cured patient without non-characterized nodules developed HCC.
      • Larger studies are needed to define the HCC risk in F3 cured patients.

      Background & Aims

      Recognition of non-characterized liver nodules (NCLN) prior to direct-acting antivirals (DAAs) is associated with increased hepatocellular carcinoma (HCC) risk in patients with HCV. The risk of HCC has not been defined in F3/F4 patients in whom NCLN have been ruled-out before starting DAAs and at sustained virological response (SVR). This study aimed to estimate HCC incidence in this population.

      Methods

      We performed a prospective study including HCV-infected patients with F3/F4 fibrosis, without a history of HCC, and who achieved SVR after DAAs. Patients were only included if they had undergone ultrasound imaging that excluded the presence of HCC/NCLN within 30 days after SVR. All patients were evaluated every 6 months until developing primary liver cancer, death or withdrawal of informed consent. HCC incidence was expressed per 100 patient-years (/100PY). Adherence to screening program was calculated every 6 months for the first 48 months.

      Results

      A total of 185 patients (63/122, F3/F4) were included. Among those with cirrhosis, 92% were Child-Pugh A and 42.7% had clinically significant portal hypertension (CSPH). Albumin-bilirubin score was 1 in 84.9% and 2 in 15.1% of patients, respectively. The median clinical and radiologic follow-up was 52.4 months and 48 months, respectively. Ten patients developed HCC: HCC incidence was 1.46/100PY (95% CI 0.79-2.71) in the whole cohort, 2.24/100PY (95% CI 1.21-4.17) in F4 only and 3.63/100PY (95% CI 1.95–6.74) in patients with CSPH. No HCC was registered in patients with F3. Median time between SVR and HCC occurrence was 28.1 months; 12 non-primary liver cancers were also identified.

      Conclusions

      Patients with cirrhosis without NCLN at SVR remain at risk of HCC development. The absence of HCC in patients with F3 reinforces their marginal cancer risk, but prospective studies are needed to exclude them from screening programs.

      Lay summary

      Patients with HCV-related cirrhosis, without non-characterized liver nodules at sustained virologic response, remain at risk of hepatocellular carcinoma despite viral cure. However, the cancer risk after successful direct-acting antiviral treatment is marginal in patients with F3 fibrosis without non-characterized liver nodules. If confirmed in larger prospective studies, current screening recommendations may need to be revisited in this group of patients.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Journal of Hepatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • European Association for the Study of the Liver
        EASL recommendations on treatment of hepatitis C: Final update of the series☆.
        J Hepatol. 2020; 73: 1170-1218https://doi.org/10.1016/j.jhep.2020.08.018
        • Afdhal N.
        • Everson G.T.
        • Calleja J.L.
        • McCaughan G.W.
        • Bosch J.
        • Brainard D.M.
        • et al.
        Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
        J Viral Hepat. 2017; 24: 823-831https://doi.org/10.1111/jvh.12706
        • Lens S.
        • Alvarado-Tapias E.
        • Mariño Z.
        • Londoño M.C.
        • LLop E.
        • Martinez J.
        • et al.
        Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis.
        Gastroenterology. 2017; 153: 1273-1283.e1https://doi.org/10.1053/j.gastro.2017.07.016
        • Lens S.
        • Baiges A.
        • Alvarado-Tapias E.
        • LLop E.
        • Martinez J.
        • Fortea J.I.
        • et al.
        Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension.
        J Hepatol. 2020; 73: 1415-1424https://doi.org/10.1016/j.jhep.2020.05.050
        • Mandorfer M.
        • Kozbial K.
        • Schwabl P.
        • Chromy D.
        • Semmler G.
        • Stättermayer A.F.
        • et al.
        Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic response to interferon-free therapy.
        Hepatology. 2020; 71: 1023-1036https://doi.org/10.1002/hep.30885
        • Crespo G.
        • Trota N.
        • Londoño M.C.
        • Mauro E.
        • Baliellas C.
        • Castells L.
        • et al.
        The efficacy of direct anti-HCV drugs improves early post-liver transplant survival and induces significant changes in waiting list composition.
        J Hepatol. 2018; 69: 11-17https://doi.org/10.1016/j.jhep.2018.02.012
        • Rodríguez-Tajes S.
        • Pocurull A.
        • Castillo J.
        • Casanova G.
        • Vega L.
        • Lens S.
        • et al.
        Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025.
        J Hepatol. 2020; 73: 1360-1367https://doi.org/10.1016/j.jhep.2020.07.018
        • Negro F.
        Residual risk of liver disease after hepatitis C virus eradication.
        J Hepatol. 2021; https://doi.org/10.1016/j.jhep.2020.11.040
        • Conti F.
        • Buonfiglioli F.
        • Scuteri A.
        • Crespi C.
        • Bolondi L.
        • Caraceni P.
        • et al.
        Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.
        J Hepatol. 2016; 65: 727-733https://doi.org/10.1016/j.jhep.2016.06.015
        • Reig M.
        • Boix L.
        • Mariño Z.
        • Torres F.
        • Forns X.
        • Bruix J.
        Liver cancer emergence associated with antiviral treatment: an immune surveillance failure?.
        Semin Liver Dis. 2017; 37: 109-118https://doi.org/10.1055/s-0037-1601349
        • Calvaruso V.
        • Cabibbo G.
        • Cacciola I.
        • Petta S.
        • Madonia S.
        • Bellia A.
        • et al.
        Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents.
        Gastroenterology. 2018; 155: 411-421.e4https://doi.org/10.1053/j.gastro.2018.04.008
        • Mariño Z.
        • Darnell A.
        • Lens S.
        • Sapena V.
        • Díaz A.
        • Belmonte E.
        • et al.
        Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules.
        J Hepatol. 2019; 70: 874-884https://doi.org/10.1016/j.jhep.2019.01.005
        • Sangiovanni A.
        • Alimenti E.
        • Gattai R.
        • Filomia R.
        • Parente E.
        • Valenti L.
        • et al.
        Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis.
        J Hepatol. 2020; 73: 593-602https://doi.org/10.1016/j.jhep.2020.03.030
        • Kanwal F.
        • Kramer J.R.
        • Asch S.M.
        • Cao Y.
        • Li L.
        • El-Serag H.B.
        Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents.
        Hepatology. 2020; 71: 44-55https://doi.org/10.1002/hep.30823
        • Pons M.
        • Rodríguez-Tajes S.
        • Esteban J.I.
        • Mariño Z.
        • Vargas V.
        • Lens S.
        • et al.
        Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals.
        J Hepatol. 2020; 72: 472-480https://doi.org/10.1016/j.jhep.2019.10.005
        • Alonso S.
        • Manzano M.L.
        • Gea F.
        • Gutiérrez M.L.
        • Ahumada A.M.
        • Devesa M.J.
        • et al.
        A model based on non-invasive markers predicts very low hepatocellular carcinoma risk after viral response in HCV-advanced fibrosis.
        Hepatology. 2020; https://doi.org/10.1002/hep.31588
        • Carrat F.
        • Fontaine H.
        • Dorival C.
        • Simony M.
        • Diallo A.
        • Hezode C.
        • et al.
        Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.
        Lancet. 2019; 393: 1453-1464https://doi.org/10.1016/S0140-6736(18)32111-1
        • Ioannou G.N.
        • Tang W.
        • Beste L.A.
        • Tincopa M.A.
        • Su G.L.
        • Van T.
        • et al.
        Assessment of a Deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis.
        JAMA Netw Open. 2020; 3e2015626https://doi.org/10.1001/jamanetworkopen.2020.15626
        • Sánchez-Azofra M.
        • Fernández I.
        • García-Buey M.L.
        • Domínguez-Domínguez L.
        • Fernández-Rodríguez C.M.
        • Mancebo A.
        • et al.
        Hepatocellular carcinoma risk in hepatitis C stage-3 fibrosis after sustained virological response with direct-acting antivirals.
        Liver Int. 2021; https://doi.org/10.1111/LIV.15032
        • European Association for the Study of the Liver
        EASL clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2018; 69: 182-236https://doi.org/10.1016/j.jhep.2018.03.019
        • Colli A.
        • Fraquelli M.
        • Andreoletti M.
        • Marino B.
        • Zuccoli E.
        • Conte D.
        Severe liver fibrosis or cirrhosis: accuracy of US for detection - analysis of 300 cases.
        Radiology. 2003; 227: 89-94https://doi.org/10.1148/radiol.2272020193
        • Soresi M.
        • Giannitrapani L.
        • Cervello M.
        • Licata A.
        • Montalto G.
        Non invasive tools for the diagnosis of liver cirrhosis.
        World J Gastroenterol. 2014; 20: 18131https://doi.org/10.3748/WJG.V20.I48.18131
        • Llop E.
        • Berzigotti A.
        • Reig M.
        • Erice E.
        • Reverter E.
        • Seijo S.
        • et al.
        Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors.
        J Hepatol. 2012; 56: 103-108https://doi.org/10.1016/j.jhep.2011.06.027
        • de Franchis R.
        • Faculty B.V.
        Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension.
        2015https://doi.org/10.1016/j.jhep.2015.07.001
        • Bureau C.
        • Metivier S.
        • Peron J.M.
        • Selves J.
        • Robic M.A.
        • Gourraud P.A.
        • et al.
        Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease.
        Aliment Pharmacol Ther. 2008; 27: 1261-1268https://doi.org/10.1111/j.1365-2036.2008.03701.x
        • European Association for the Study of the Liver
        EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update.
        J Hepatol. 2021; 75: 659-689https://doi.org/10.1016/j.jhep.2021.05.025
        • European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer
        EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.
        J Hepatol. 2012; 56: 908-943https://doi.org/10.1016/j.jhep.2011.12.001
        • Forner A.
        • Reig M.
        • Bruix J.
        Hepatocellular carcinoma.
        Lancet. 2018; 391: 1301-1314https://doi.org/10.1016/S0140-6736(18)30010-2
        • Baumert T.F.
        The Nobel prize in medicine 2020 for the discovery of hepatitis C virus: transforming hepatology.
        J Hepatol. 2020; 73: 1303-1305https://doi.org/10.1016/j.jhep.2020.10.017
        • Blach S.
        • Zeuzem S.
        • Manns M.
        • Altraif I.
        • Duberg A.-S.
        • Muljono D.H.
        • et al.
        Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.
        Lancet Gastroenterol Hepatol. 2017; 2: 161-176https://doi.org/10.1016/S2468-1253(16)30181-9
        • Nahon P.
        • Layese R.
        • Bourcier V.
        • Cagnot C.
        • Marcellin P.
        • Guyader D.
        • et al.
        Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs.
        Gastroenterology. 2018; 155: 1436-1450.e6https://doi.org/10.1053/j.gastro.2018.07.015
        • Mendizabal M.
        • Piñero F.
        • Ridruejo E.
        • Herz Wolff F.
        • Anders M.
        • Reggiardo V.
        • et al.
        Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents.
        Clin Gastroenterol Hepatol. 2020; 18: 2554-2563.e3https://doi.org/10.1016/j.cgh.2020.02.044
        • Ravi S.
        • Axley P.
        • Jones D.A.
        • Kodali S.
        • Simpson H.
        • McGuire B.M.
        • et al.
        Unusually high rates of hepatocellular carcinoma after treatment with direct-acting antiviral therapy for hepatitis C related cirrhosis.
        Gastroenterology. 2017; 152: 911-912https://doi.org/10.1053/j.gastro.2016.12.021
        • Degasperi E.
        • D’Ambrosio R.
        • Iavarone M.
        • Sangiovanni A.
        • Aghemo A.
        • Soffredini R.
        • et al.
        Factors associated with increased risk of de novo or recurrent hepatocellular carcinoma in patients with cirrhosis treated with direct-acting antivirals for HCV infection.
        Clin Gastroenterol Hepatol. 2019; 17: 1183-1191.e7https://doi.org/10.1016/j.cgh.2018.10.038
        • Beste L.A.
        • Green P.K.
        • Berry K.
        • Kogut M.J.
        • Allison S.K.
        • Ioannou G.N.
        Effectiveness of hepatitis C antiviral treatment in a USA cohort of veteran patients with hepatocellular carcinoma.
        J Hepatol. 2017; 67: 32-39https://doi.org/10.1016/j.jhep.2017.02.027
        • Backus L.I.
        • Belperio P.S.
        • Shahoumian T.A.
        • Mole L.A.
        Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease.
        Hepatology. 2019; 69: 487-497https://doi.org/10.1002/hep.29408
        • Fan R.
        • Papatheodoridis G.
        • Sun J.
        • Innes H.
        • Toyoda H.
        • Xie Q.
        • et al.
        aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis.
        J Hepatol. 2020; 73: 1368-1378https://doi.org/10.1016/j.jhep.2020.07.025
        • Audureau E.
        • Carrat F.
        • Layese R.
        • Cagnot C.
        • Asselah T.
        • Guyader D.
        • et al.
        Personalized surveillance for hepatocellular carcinoma in cirrhosis – using machine learning adapted to HCV status.
        J Hepatol. 2020; 73: 1434-1445https://doi.org/10.1016/j.jhep.2020.05.052
        • Farhang Zangneh H.
        • Wong W.W.L.
        • Sander B.
        • Bell C.M.
        • Mumtaz K.
        • Kowgier M.
        • et al.
        Cost effectiveness of hepatocellular carcinoma surveillance after a sustained virologic response to therapy in patients with hepatitis C virus infection and advanced fibrosis.
        Clin Gastroenterol Hepatol. 2019; 17: 1840-1849.e16https://doi.org/10.1016/j.cgh.2018.12.018
        • Allaire M.
        • Nahon P.
        • Layese R.
        • Bourcier V.
        • Cagnot C.
        • Marcellin P.
        • et al.
        Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
        Hepatology. 2018; 68: 1245-1259https://doi.org/10.1002/hep.30034
        • Sanduzzi-Zamparelli M.
        • Boix L.
        • Leal C.
        • Reig M.
        Hepatocellular carcinoma recurrence in HCV patients treated with direct antiviral agents.
        Viruses. 2019; 11https://doi.org/10.3390/v11050406
        • Gaglio P.J.
        Extrahepatic and intrahepatic malignancies in patients with HCV who achieve an SVR with directly acting antiviral agents: should we be concerned that DAA therapy contributed to this phenomenon?.
        J Clin Gastroenterol. 2017; 51: 657-658https://doi.org/10.1097/MCG.0000000000000892
        • Amaddeo G.
        • Nguyen C.T.
        • Maillé P.
        • Mulé S.
        • Luciani A.
        • Machou C.
        • et al.
        Intrahepatic immune changes after hepatitis c virus eradication by direct-acting antiviral therapy.
        Liver Int. 2020; 40: 74-82https://doi.org/10.1111/liv.14226